Follow

Biovica International AB

Nasdaq First North GM Stockholm (Sweden)

Biovica is a biotech company which develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Media
Rights issue
Price
8.65 SEK
Subscription period
21 Nov - 05 Dec 2022
News
1 2 3 4 5
Show

20

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
BIOVIC B
SE0008613731
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Biovica International AB with ticker BIOVIC B
Status
Active
Amount of instruments
21 875 512
Currency
SEK
Segment
First North Premier
First trading date
29 Mar 2017
Private placement
Sign in to buy
Private placement
Sign in to buy
Type
Price
Pre-money
Time
Files
Rights issue
8.65 SEK
247.29M SEK
21 Nov - 05 Dec 2022
Share issue in Biovica International AB
People
Anders Rylander
CEO
Lars Holmqvist
Chairman of the board
Maria Holmlund
Board member
Ulf Jungnelius
Board member
Henrik Osvald
Board member
Jesper Söderqvist
Board member
Anders Rylander
Board member
Annika Berg
Board member
Marie-Louise Fjällskog
Board member
Company Details
Sector
HEALTH CARE
Website

Address
Dag Hammarskjölds väg 54 B
Zip code
752 37
City/district
Uppsala
Country
Sweden (SE)
Registration number
556774-6150
LEI code
549300VADE1VRR555N78
First trade date
29 Mar 2017
Registration date
03 Jan 2009
Short name
BIOVIC

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More